Investor Relations

Press Releases

 
Press Releases
  Date Title and Summary View
Oct 18, 2017
- Conference Call Scheduled for Thursday, November 2, 2017 at 4:30pm ET - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that th...
Oct 18, 2017
- Company expects to report topline eight-week results at the end of the year - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions, today ann...
Sep 19, 2017
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in the Cantor Fitzgerald 2017 Global Healthcare Conference in New York, NY. ...
Sep 6, 2017
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions, today announced that Mark Foley has been appointed to Revance's Board of Directors, effective September 5, 2017. ...
Aug 30, 2017
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in the 2017 Wells Fargo Securities Healthcare Conference in Boston, MA. ...
Aug 3, 2017
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions, today announced results for the second quarter ended JuneĀ 30, 2017. Recent Highlights and Upcom...
Aug 2, 2017
NEWARK, Calif., August 2, 2017 – Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in treating aesthetic and therapeutic conditions, today announced the expansion of its executive leadership team with the appointment of Todd Zavodnick as Chief Commercial Officer and President, Aesthet...
Jul 24, 2017
Conference Call Scheduled for Thursday, August 3, 2017 at 4:30pm ET NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will...
Jun 15, 2017
- RT002 injectable 40-unit dose under study for the treatment of glabellar lines demonstrated statistical and clinical superiority over BOTOX* Cosmetic for a range of efficacy outcomes and achieved six-month duration of effect - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics...
Jun 5, 2017
- Poster on display today to be presented during late-breaking session on June 7, 2017, at 21st International Congress of Parkinson's Disease and Movement Disorders - NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company developing botu...
Page:
1
... NextLast
= add release to Briefcase
Shareholder Tools